Modulation of Alzheimer-like synaptic and cholinergic deficits in transgenic mice by human apolipoprotein E depends on isoform, aging, and overexpression of amyloid β peptides but not on plaque formation

Journal of Neuroscience

Volumn 22, Issue 24, 2002, Pages 10539-10548

  Buttini, Manuel ^a   Yu, Gui Qiu ^a   Shockley, Kristina ^a   Huang, Yadong ^a   Jones, Brian ^a   Masliah, Eliezer ^c   Mallory, Margaret ^c   Yeo, Tracy ^b,d   Longo, Frank M ^b,d   Mucke, Lennart ^a,b,e  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e NONE   (United States)

Author keywords

Acetylcholine; Aging; Alzheimer's disease; Amyloid; Apolipoprotein E; Cholinergic; Neurodegeneration; Synapses; Transgenic

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN E; APOLIPOPROTEIN E3; APOLIPOPROTEIN E4; ISOPROTEIN; SYNAPTOPHYSIN;

AGING; ALZHEIMER DISEASE; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHOLINERGIC TRANSMISSION; COGNITION; CONTROLLED STUDY; CORRELATION ANALYSIS; GENE OVEREXPRESSION; IMMUNOREACTIVITY; MOUSE; NERVE DEGENERATION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; SENILE PLAQUE; SYNAPSE; TRANSGENIC MOUSE;

EID: 0037115049     PISSN: 02706474     EISSN: None     Source Type: Journal    
DOI: 10.1523/jneurosci.22-24-10539.2002     Document Type: Article

References (108)

1. Allen SJ, MacGowan SH, Tyler S, Wilcock GK, Robertson AGS, Holden PH, Smith SKF, Dawbarn D (1997) Reduced cholinergic function in normal and Alzheimer's disease brain is associated with apolipoprotein E4 genotype. Neurosci Lett 239:33-36.
2. Arendt T, Schindler C, Brückner MK, Eschrich K, Bigl V, Zedlick D, Marcova L (1997) Plastic neuronal remodeling is impaired in patients with Alzheimer's disease carrying apolipoprotein E4 allele. J Neurosci 17:516-529.
3. Berr C, Hauw J-J, Delaäre P, Duyckaerts C, Amouyel P (1994) Apolipoprotein E allele 4 is linked to increased deposition of the amyloid β-peptide (A-β) in cases with or without Alzheimer's disease. Neurosci Lett 178:221-224.
4. Bierer L, Haroutunian V, Gabriel S, Knott PJ, Carlin LS, Purohit DP, Perl DP, Schmeidler J, Kanof P, Davis KL (1995) Neurochemical correlates of dementia severity in Alzheimer's disease: Relative importance of the cholinergic deficits. J Neurochem 64:749-760.
5. Boncristiano S, Calhoun ME, Kelly PH, Pfeifer M, Bondolfi L, Stalder M, Phinney AL, Abramowski D, Sturchler-Pierrat C, Enz A, Sommer B, Staufenbiel M, Jucker M (2002) Cholinergic changes in the APP23 transgenic mouse model of cerebral amyloidosis. J Neurosci 22:3234-3243.
6. Bookheimer SY, Strojwas MH, Cohen MS, Saunders AM, Pericak-Vance MA, Mazziotta JC, Small GW (2000) Patterns of brain activation in people at risk for Alzheimer's disease. N Engl J Med 343:450-456.
7. Boyles JK, Pitas RE, Wilson E, Mahley RW, Taylor JM (1985) Apolipoprotein E associated with astrocytic glia of the central nervous system and with nonmyelinating glia of the peripheral nervous system. J Clin Invest 76:1501-1513.
8. Bronfman FC, Tesseur I, Hofker MH, Havekens LM, Van Leuven F (2000) No evidence for cholinergic problems in apolipoprotein E knockout and apolipoprotein E4 transgenic mice. Neuroscience 97:411-418.
9. Brown DF, Risser RC, Bigio EH, Tripp P, Stiegler A, Welch E, Eagan KP, Hladik CL, White CLI (1998) Neocortical synapse density and Braak stage in the Lewy body variant of Alzheimer disease: A comparison with classic Alzheimer disease and normal aging. J Neuropathol Exp Neurol 57:955-960.
10. Buttini M, Orth M, Bellosta S, Akeefe H, Pitas RE, Wyss-Coray T, Mucke L, Mahley RW (1999) Expression of human apolipoprotein E3 or E4 in the brains of Apoe-/- mice: Isoform-specific effects on neurodegeneration. J Neurosci 19:4867-4880.
11. Buttini M, Akeefe H, Lin C, Mahley RW, Pitas RE, Wyss-Coray T, Mucke L (2000) Dominant negative effects of apolipoprotein E4 revealed in transgenic models of neurodegenerative disease. Neuroscience 97:207-210.
12. Calhoun ME, Wiederhold KH, Abramowski D, Phinney AL, Probst A, Sturchler-Pierrat C, Staufenbiel M, Sommer B, Jucker M (1998) Neuron loss in APP transgenic mice. Nature 395:755-756.
13. Caselli RJ, Graff-Radford NR, Reiman M, Weaver A, Osborne D, Lucas J, Uecker A, Thibodeau SN (1999) Preclinical memory decline in cognitively normal apolipoprotein E-E4 homozygotes. Neurology 53:201-207.
14. Caselli RJ, Osborne D, Reiman EM, Hentz JG, Barbieri CJ, Saunders AM, Hardy J, Graff-Radford NR, Hall GR, Alexander GE (2001) Preclinical cognitive decline in late middle-aged asymptomatic apolipoprotein E-ε4/4 homozygotes: A replication study. J Neurol Sci 189:93-98.
15. Chapman J, Korczyn AD, Karussis DM, Michaelson DM (2001) The effects of APOE genotype on age at onset and progression of neurodegenerative diseases. Neurology 57:1482-1485.
16. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, Roses AD, Haines JL, Pericak-Vance MA (1993) Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261:921-923.
17. Corey-Bloom J, Tiraboschi P, Hansen LA, Alford M, Schoos B, Sabbagh MN, Masliah E, Thal LJ (2000) E4 allele dosage does not predict cholinergic activity or synapse loss in Alzheimer's disease. Neurology 54:403-406.
18. Cummings JL (2000) Cholinesterase inhibitors: A new class of psychotropic compounds. Am J Psychiatry 157:4-15.
19. Davies P (1979) Neurotransmitter-related enzymes in senile dementia of the Alzheimer type. Brain Res 171:319-327.
20. Davis JN, Chisholm JC (1997) The "amyloid cascade hypothesis" of AD: Decoy or real McCoy? Trends Neurosci 20:558-559.
21. DeKosky ST, Scheff SW (1990) Synapse loss in frontal cortex biopsies in Alzheimer's disease: Correlation with cognitive severity. Ann Neurol 27:457-464.
22. Dekroon RM, Armati PJ (2001) Synthesis and processing of apolipoprotein E in human brain cultures. Glia 33:298-305.
23. Dong LM, Weisgraber KH (1996) Human apolipoprotein E4 domain interaction. Arginine 61 and glutamic acid 255 interact to direct the preference for very low density lipoproteins. J Biol Chem 271:19053-19057.
24. Farlow MR, Lahiri DK, Poirier J, Davignon J, Schneider L, Hui SL (1998) Treatment outcome of tacrine therapy depends on apolipoprotein genotype and gender of the subjects with Alzheimer's disease. Neurology 50:669-677.
25. Farrer LA, Cupples LA, Haines JL, Hyman B, Kukull WA, Mayeux R, Myers RH, Pericak-Vance MA, Risch N, van Duijn CM (1997) Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. JAMA 278:1349-1356.
26. Games D, Adams D, Alessandrini R, Barbour R, Berthelette P, Blackwell C, Carr T, Clemens J, Donaldson T, Gillespie F, Guido T, Hagopian S, Johnson-Wood K, Khan K, Lee M, Leibowitz P, Lieberburg I, Little S, Masliah E, McConlogue L, et al (1995) Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein. Nature 373:523-527.
27. Gearing M, Mori H, Mirra SS (1996) Aβ-peptide length and apolipoprotein E genotype in Alzheimer's disease. Ann Neurol 39:395-399.
28. Geula C, Wu CK, Saroff D, Lorenzo A, Yuan J, Yankner BA (1998) Aging renders the brain vulnerable to amyloid β-protein neurotoxicity. Nat Med 4:827-831.
29. Gilmor ML, Erickson JD, Varoqui H, Hersh LB, Bennett DA, Cochran EJ, Mufson EJ, Levey AI (1999) Preservation of nucleus basalis neurons containing choline acetyltransferase and the vesicular acetylcholine transporter in the elderly with mild cognitive impairment and early Alzheimer's disease. J Comp Neurol 411:693-704.
30. Gordon I, Grauer E, Genis I, Sehayek E, Michaelson DM (1995) Memory deficits and cholinergic impairments in apolipoprotein E-deficient mice. Neurosci Lett 199:1-4.
31. Greenwood PM, Sunderland T, Friz JL, Parasuraman R (2000) Genetics and visual attention: Selective deficits in healthy adult carriers of the Cε4 allele of the apolipoprotein E gene. Proc Natl Acad Sci USA 97:11661-11666.
32. Hartley DM, Walsh DM, Ye CP, Diehl T, Vasquez S, Vassilev PM, Teplow DB, Selkoe DJ (1999) Protofibrillar intermediates of amyloid β-protein induce acute electrophysiological changes and progressive neurotoxicity in cortical neurons. J Neurosci 19:8876-8884.
33. Heinonen O, Lehtovirta M, Soininen H, Helisalmi S, Mannermaa A, Sorvari H, Kosunen O, Paljärvi L, Ryynänen M, Riekkinen Sr PJ (1995) Alzheimer pathology of patients carrying apolipoprotein E ε4 allele. Neurobiol Aging 16:505-513.
34. Holcomb LA, Gordon MN, Jantzen P, Hsiao K, Duff K, Morgan D (1999) Behavioral changes in transgenic mice expressing both amyloid precursor protein and presenilin-1 mutations: Lack of association with amyloid deposits. Behav Genet 29:177-185.
35. Holtzman DM, Fagan AM (1998) Potential role of apoE in structural plasticity in the nervous system. Implications for disorders of the central nervous system. Trends Cardiovasc Med 8:250-255.
36. Holtzman DM, Bales KR, Wu S, Bhat P, Parsadanian M, Fagan AM, Chang LK, Sun Y, Paul SM (1999) Expression of human apolipoprotein E reduces amyloid-β deposition in a mouse model of Alzheimer's disease. J Clin Invest 103:R15-R21.
37. Holtzman DM, Bales KR, Tenkova T, Fagan AM, Parsadanian M, Sartorius LJ, Mackey B, Olney J, McKeel D, Wozniak D, Paul SM (2000a) Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 97:2892-2897.
38. Holtzman DM, Fagan AM, Mackey B, Tenkova T, Sartorius L, Paul SM, Bales K, Ashe KH, Irizarry MC, Hyman BT (2000b) Apolipoprotein E facilitates neuritic and cerebrovascular plaque formation in an Alzheimer's disease model. Ann Neurol 47:739-747.
39. Horsburgh K, McCulloch J, Nilsen M, Roses AD, Nicoll JAR (2000) Increased neuronal damage and apoE immunoreactivity in human apolipoprotein E, E4 isoform-specific, transgenic mice after global cerebral ischaemia. Eur J Neurosci 12:4309-4317.
40. Hsia A, Masliah E, McConlogue L, Yu G, Tatsuno G, Hu K, Kholodenko D, Malenka RC, Nicoll RA, Mucke L (1999) Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models. Proc Natl Acad Sci USA 96:3228-3233.
41. Huang Y, Schwendner SW, Rall Jr SC, Mahley RW (1996) Hypolipidemic and hyperlipidemic phenotypes in transgenic mice expressing human apolipoprotein E2. J Biol Chem 271:29146-29151.
42. Huang Y, Liu XQ, Wyss-Coray T, Brecht WJ, Sanan DA, Mahley RW (2001) Apolipoprotein E fragments present in Alzheimer's disease brains induce neurofibrillary tangle-like intracellular inclusions in neurons. Proc Natl Acad Sci USA 98:8838-8843.
43. Hyman BT, West HL, Rebeck GW, Buldyrev SV, Mantegna RN, Ukleja M, Havlin S, Stanley HE (1995) Quantitative analysis of senile plaques in Alzheimer disease: Observation of log-normal size distribution and molecular epidemiology of differences associated with apolipoprotein E genotype and trisomy 21 (Down syndrome). Proc Natl Acad Sci USA 92:3586-3590.
44. Ishii K, Tamaoka A, Mizusawa H, Shoji S, Ohtake T, Fraser PE, Takahashi H, Tsuji S, Gearing M, Mizutani T, Yamada S, Kato M, St. George-Hyslop PH, Mirra SS, Mori H (1997) Aβ1-40 but not Aβ1-42 levels in cortex correlate with apolipoprotein E ε4 allele dosage in sporadic Alzheimer's disease. Brain Res 748:250-252.
45. Ji ZS, Pitas RE, Mahley RW (1998) Differential cellular accumulation/retention of apolipoprotein E mediated by cell surface heparan sulfate proteoglycans. J Biol Chem 273:13452-13460.
46. Ji ZS, Miranda RD, Newhouse YM, Weisgraber KH, Huang Y, Mahley RW (2002) Apolipoprotein E4 potentiates amyloid β peptide-induced lysosomal leakage and apoptosis in neuronal cells. J Biol Chem 277:21821-21828.
47. Johnson JK, McCleary R, Oshita MH, Cotman CW (1998) Initiation and propagation stages of β-amyloid are associated with distinctive apolipoprotein E, age, and gender profiles. Brain Res 798:18-24.
48. 42 deposition in a transgenic mouse model of Alzheimer disease. Proc Natl Acad Sci USA 94:1550-1555.
49. Klein WL, Krafft GA, Finch CE (2001) Targeting small Aβ oligomers: The solution to an Alzheimer's disease conundrum. Trends Neurosci 24:219-224.
50. Knowles RB, Wyart C, Buldyrev SV, Cruz L, Urbanc B, Hasselmo ME, Stanley HE, Hyman BT (1999) Plaque-induced neurite abnormalities: Implications for disruption of neural networks in Alzheimer's disease. Proc Natl Acad Sci USA 96:5274-5279.
51. 1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci USA 95:6448-6453.
52. Langlais PJ, Thal L, Hansen L, Galasko D, Alford M, Masliah E (1993) Neurotransmitters in basal ganglia and cortex of Alzheimer's disease with and without Lewy bodies. Neurology 43:1927-1934.
53. Lue L-F, Kuo Y-M, Roher AE, Brachova L, Shen Y, Sue L, Beach T, Kurth JH, Rydel RE, Rogers J (1999) Soluble amyloid β peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am J Pathol 155:853-862.
54. Ma J, Brewer Jr HB, Potter H (1996) Alzheimer Aβ neuroroxicity: Promotion by antichymotrypsin, ApoE4: Inhibition by Aβ-related peptides. Neurobiol Aging 17:773-780.
55. Mahley R, Huang Y (1999) Apolipoprotein E: From atherosclerosis to Alzheimer's disease and beyond. Curr Opin Lipidol 10:207-217.
56. Masliah E, Mallory M, Alford M, Ge N, Mucke L (1995a) Abnormal synaptic regeneration in hAPP695 transgenic and apoE knockout mice. In: Research Advances in Alzheimer's Disease and Related Disorders (Iqbal K, Mortimer J, Winblad B, Wisniewski H, eds), pp 405-414. New York: Wiley.
57. Masliah E, Mallory M, Ge N, Alford M, Veinbergs I, Roses AD (1995b) Neurodegeneration in the central nervous system of apoE-deficient mice. Exp Neurol 136:107-122.
58. Masliah E, Sisk A, Mallory M, Mucke L, Schenk D, Games D (1996) Comparison of neurodegenerative pathology in transgenic mice overexpressing V717F β-amyloid precursor protein and Alzheimer's disease. J Neurosci 16:5795-5811.
59. Masliah E, Rockenstein E, Veinbergs I, Sagara Y, Mallory M, Hashimoto M, Mucke L (2001) β-amyloid peptides enhance α-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease. Proc Natl Acad Sci USA 98:12245-12250.
60. Mauch DH, Nägler K, Schumacher S, Göritz C, Müller E-C, Otto A, Pfrieger FW (2001) CNS synaptogenesis promoted by glia-derived cholesterol. Science 294:1354-1357.
61. McLean CA, Cherny RA, Fraser FW, Fuller SJ, Smith MJ, Beyreuther K, Bush AI, Masters CL (1999) Soluble pool of Aβ amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann Neurol 46:860-866.
62. McNamara MJ, Gomez-Isla T, Hyman BT (1998) Apolipoprotein E genotype and deposits of Aβ40 and Aβ42 in Alzheimer disease. Arch Neurol 55:1001-1004.
63. Miyata M, Smith JD (1996) Apolipoprotein E allele-specific antioxidant activity and effects on cytotoxicity by oxidative insults and β-amyloid peptides. Nat Genet 14:55-61.
64. 1-42 in wild-type human amyloid protein precursor transgenic mice: Synaptotoxicity without plaque formation. J Neurosci 20:4050-4058.
65. Nakano S, Asada T, Matsuda H, Uno M, Takasaki M (2001) Donepezil hydrochloride preserves regional cerebral blood flow in patients with Alzheimer's disease. J Nucl Med 42:1441-1445.
66. Nalbantoglu J, Tirado-Santiago G, Lahasaïni A, Poirier J, Goncalves O, Verge G, Momoli F, Welner SA, Massicotte G, Julien JP, Shapiro ML (1997) Impaired learning and LTP in mice expressing the carboxy terminus of the Alzheimer amyloid precursor protein. Nature 387:500-505.
67. Näslund J, Haroutunian V, Mohs R, Davis KL, Davies P, Greengard P, Buxbaum JD (2000) Correlation between elevated levels of amyloid β-peptide in the brain and cognitive decline. JAMA 283:1571-1577.
68. Nathan BP, Bellosta S, Sanan DA, Weisgraber KH, Mahley RW, Pitas RE (1994) Differential effects of apolipoproteins E3 and E4 on neuronal growth in vitro. Science 264:850-852.
69. Nathan BP, Chang K-C, Bellosta S, Brisch E, Ge N, Mahley RW, Pitas RE (1995) The inhibitory effect of apolipoprotein E4 on neurite outgrowth is associated with microtubule depolymerization. J Biol Chem 270:19791-19799.
70. Neary D, Snowden JS, Mann DMA, Bowen DM, Sims NR, Northen B, Yates PO, Davison AN (1986) Alzheimer's disease: A correlative study. J Neurol Neurosurg Psychiatry 49:229-237.
71. 1-42) and forms slowly sedimenting Aβ complexes that cause oxidative stress. Exp Neurol 136:22-31.
72. Permanne B, Perez C, Soto C, Frangione B, Wisniewski T (1997) Detection of apolipoprotein E/dimeric soluble amyloid β complexes in Alzheimer's disease brain supernatants. Biochem Biophys Res Commun 240:715-720.
73. Perry EK, Tomlinson BE, Blessed G, Bergmann K, Gibson PH, Perry RH (1978) Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. Br Med J 2:1457-1459.
74. Pike CJ, Burdick D, Walencewicz AJ, Glabe CG, Cotman CW (1993) Neurodegeneration induced by β-amyloid peptides in vitro: The role of peptide assembly state. J Neurosci 13:1676-1687.
75. Poirier J, Delisle MC, Quirion R, Aubert I, Farlow M, Lahiri D, Hui S, Bertrand P, Nalbantoglu J, Gilfix BM, Gauthier S (1995) Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer disease. Proc Natl Acad Sci USA 92:12260-12264.
76. Price DL, Sisodia SS, Borchelt DR (1998) Genetic neurodegenerative diseases: The human illness and transgenic models. Science 282:1079-1083.
77. Raber J, Wong D, Buttini M, Orth M, Bellosta S, Pitas RE, Mahley RW, Mucke L (1998) Isoform-specific effects of human apolipoprotein E on brain function revealed in ApoE knockout mice: Increased susceptibility of females. Proc Natl Acad Sci USA 95:10914-10919.
78. Raber J, Wong D, Yu G-Q, Buttini M, Mahley RW, Pitas RE, Mucke L (2000) Alzheimer's disease: Apolipoprotein E and cognitive performance. Nature 404:352-354.
79. Raber J, LeFevour A, Buttini M, Mucke L (2002) Androgens protect against apolipoprotein E4-induced cognitive deficits. J Neurosci 22:5204-5209.
80. Raffaï RL, Dong LM, Farese Jr RV, Weisgraber KH (2001) Introduction of human apolipoprotein E4 "domain interaction" into mouse apolipoprotein E. Proc Natl Acad Sci USA 98:11587-11591.
81. Rebeck GW, Reiter JS, Strickland DK, Hyman BT (1993) Apolipoprotein E in sporadic Alzheimer's disease: Allelic variation and receptor interactions. Neuron 11:575-580.
82. Reiman EM, Caselli RJ, Chen KW, Alexander GE, Bandy D, Frost J (2001) Declining brain activity in cognitively normal apolipoprotein E Cε4 heterozygotes: A foundation for using positron emission tomography to efficiently test treatments to prevent Alzheimer's disease. Proc Natl Acad Sci USA 98:3334-3339.
83. Sabo T, Lomnitski L, Nyska A, Beni S, Maronpot RR, Shohami E, Roses AD, Michaelson DM (2000) Susceptibility of transgenic mice expressing human apolipoprotein E to closed head injury: The allele E3 is neuroprotective whereas E4 increases fatalities. Neuroscience 101:879-884.
84. Salehi A, Dubelaar EJG, Mulder M, Swaab DF (1998) Aggravated decrease in the activity of nucleus basalis neurons in Alzheimer's disease is apolipoprotein E-type dependent. Proc Natl Acad Sci USA 95:11445-11449.
85. Samuel W, Alford M, Hofstetter CR, Hansen L (1997) Dementia with Lewy bodies versus pure Alzheimer disease: Differences in cognition, neuropathology, cholinergic dysfunction, and synapse density. J Neuropathol Exp Neurol 56:499-508.
86. Schmechel DE, Saunders AM, Strittmatter WJ, Crain BJ, Hulette CM, Joo SH, Pericak-Vance MA, Goldgaber D, Roses AD (1993) Increased amyloid β-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. Proc Natl Acad Sci USA 90:9649-9653.
87. Schmidt ML, Robinson KA, Lee VM-Y, Trojanowski JQ (1995) Chemical and immunological heterogeneity of fibrillar amyloid in plaques of Alzheimer's disease and Down's syndrome brains revealed by confocal microscopy. Am J Pathol 147:503-515.
88. Selkoe DJ (2001) Alzheimer's disease: Genes, proteins, and therapy. Physiol Rev 81:741-766.
89. Sheng HX, Laskowitz DT, Bennett E, Schmechel DE, Bart RD, Saunders AM, Pearlstein RD, Roses AD, Warner DS (1998) Apolipoprotein E isoform-specific differences in outcome from focal ischemia in transgenic mice. J Cereb Blood Flow Metab 18:361-366.
90. Sims NR, Bowen DM, Allen SJ, Smith CCT, Neary D, Thomas DJ, Davison AN (1983) Presynaptic cholinergic dysfunction in patients with dementia. J Neurochem 40:503-509.
91. Sjögren M, Hesse C, Basun H, Köl G, Thostrup H, Kilander L, Marcusson J, Edman Å, Wallin A, Karlsson I, Troell M, Wachtmaister G, Ekdahl A, Olofsson H, Sandström A, Andreasen N, Minthon L, Blennow K (2001) Tacrine and rate of progression in Alzheimer's disease. Relation to ApoE allele genotype. J Neural Transm 108:451-458.
92. Small GW, Ercoli LM, Silverman DHS, Huang SC, Komo S, Bookheimer SY, Lavretsky H, Miller K, Siddarth P, Rasgon NL, Mazziotta JC, Saxena S, Wu HM, Mega MS, Cummings JL, Saunders AM, Pericak-Vance MA, Roses AD, Barrio JR, Phelps ME (2000) Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease. Proc Natl Acad Sci USA 97:6037-6042.
93. Soininen H, Kosunen O, Helisalmi S, Mannermaa A, PaljÑrvi L, Talasniemi S, RyynÑnen M, Riekkinen Sr P (1995) A severe loss of choline acetyltransferase in the frontal cortex of Alzheimer patients carrying apolipoprotein ε4 allele. Neurosci Lett 187:79-82.
94. Stone DJ, Rozovsky I, Morgan TE, Anderson CP, Hajian H, Finch CE (1997) Astrocytes and microglia respond to estrogen with increased apoE mRNA in vivo and in vitro. Exp Neurol 143:313-318.
95. Strittmatter WJ, Weisgraber KH, Goedert M, Saunders AM, Huang D, Corder EH, Dong L-M, Jakes R, Alberts MJ, Gilbert JR, Han S-H, Hulette C, Einstein G, Schmechel DE, Pericak-Vance MA, Roses AD (1994) Microtubule instability and paired helical filament formation in the Alzheimer disease brain are related to apolipoprotein E genotype. Exp Neurol 125:163-171.
96. Sze CI, Troncoso JC, Kawas C, Mouton P, Price DL, Martin LJ (1997) Loss of the presynaptic vesicle protein synaptophysin in hippocampus correlates with cognitive decline in Alzheimer disease. J Neuropathol Exp Neurol 56:933-944.
97. Terry RD (1996) The pathogenesis of Alzheimer disease: An alternative to the amyloid hypothesis. J Neuropathol Exp Neurol 55:1023-1025.
98. Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R, Hansen LA, Katzman R (1991) Physical basis of cognitive alterations in Alzheimer's disease: Synapse loss is the major correlate of cognitive impairment. Ann Neurol 30:572-580.
99. Terry RD, Masliah E, Hansen LA (1999) The neuropathology of Alzheimer disease and the structural basis of its cognitive alterations. In: Alzheimer Disease, Ed 2 (Terry RD, Katzman R, Bick KL, Sisodia SS, eds), pp 187-206. Philadelphia: Lippincott Williams and Wilkins.
100. Tiraboschi P, Hansen LA, Alford M, Masliah E, Thal LJ, Corey-Bloom J (2000) The decline in synapses and cholinergic activity is asynchronous in Alzheimer's disease. Neurology 55:1278-1283.
101. Tolar M, Keller JN, Chan S, Mattson MP, Marques MA, Crutcher KA (1999) Truncated apolipoprotein E (apoE) causes increased intracellular calcium and may mediate apoE neurotoxicity. J Neurosci 19:7100-7110.
102. Wilcock GK, Esiri MM, Bowen DM, Smith CCT (1982) Alzheimer's disease: Correlation of cortical acetyltransferase activity with the severity of dementia and histological abnormalities. J Neurol Sci 57:407-417.
103. Wisniewski T, Frangione B (1992) Apolipoprotein E: A pathological chaperone protein in patients with cerebral and systemic amyloid. Neurosci Lett 135:235-238.
104. Xu PT, Gilbert JR, Qui H, Ervin J, Rothrock-Christian TR, Hulette C, Schmechel DE (1999) Specific regional transcription of apolipoprotein E in human brain neurons. Am J Pathol 154:1-11.
105. Xu Q, Li Y, Cyras C, Sanan DA, Cordell B (2000) Isolation and characterization of apolipoproteins from murine microglia. Identification of a low density lipoprotein-like apolipoprotein J-rich but E-poor spherical particle. J Biol Chem 275:31770-31777.
106. Yaffe K, Haan M, Byers A, Tangen C, Kuller L (2000) Estrogen use, APOE, and cognitive decline. Evidence of gene-environment interaction. Neurology 54:1949-1953.
107. Yankner BA (1996) Mechanisms of neuronal degeneration in Alzheimer's disease. Neuron 16:921-932.
108. NTR causes increased basal forebrain cholinergic neuron size, choline acetyltransferase activity, and target innervation. J Neurosci 17:7594-7605.